Amneal Pharmaceuticals (AMRX)
$
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
9
8
7
6
5
4
3
2
1
0
About
Business overview of Amneal Pharmaceuticals (AMRX)
Amneal Pharmaceuticals Inc is a global pharmaceutical company operating primarily in the U.S., India, and Ireland. With three reportable segments; Generics, Specialty, and AvKARE - It develop, manufacture, and distribute a diverse portfolio of essential medicines. The Generics segment focuses on a wide range of dosage forms and delivery systems, contributing significantly to revenues. The Specialty segment promotes proprietary branded pharmaceuticals, particularly targeting the central nervous system and endocrine disorders. The AvKARE segment provides pharmaceuticals and medical products to governmental agencies, specializing in re-packaging and wholesale distribution, with a focus on offering consistent care and pricing to qualified entities.
Key Insights
Critical company metrics and information
Share Price
$8.04Market Cap
$2.49 BillionTotal Outstanding Shares
309.84 Million SharesTotal Employees
7,700Dividend
No dividendIPO Date
May 7, 2018SIC Description
Pharmaceutical PreparationsHomepage
https://www.amneal.com
Historical Stock Splits
If you bought 1 share of AMRX before August 26, 2013, you'd have 0.04 shares today.
Execution Date | Split Amount |
---|---|
August 26, 2013 | 1-for-25 (Reverse Split) |
Cash Flow Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Exchange Gains/Losses | $-58,000.00 |
Net Cash Flow From Financing Activities | $-251.42 Million |
Net Cash Flow, Continuing | $-17.20 Million |
Net Cash Flow From Investing Activities | $-78.63 Million |
Net Cash Flow From Investing Activities, Continuing | $-78.63 Million |
Net Cash Flow From Operating Activities, Continuing | $312.84 Million |
Net Cash Flow From Financing Activities, Continuing | $-251.42 Million |
Net Cash Flow From Operating Activities | $312.84 Million |
Net Cash Flow | $-17.26 Million |
Income Statement
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Basic Earnings Per Share | $-0.86 |
Income/Loss From Continuing Operations Before Tax | $-123.16 Million |
Net Income/Loss | $-146.48 Million |
Revenues | $2.68 Billion |
Research and Development | $182.53 Million |
Net Income/Loss Attributable To Noncontrolling Interest | $37.98 Million |
Operating Expenses | $759.67 Million |
Costs And Expenses | $2.80 Billion |
Preferred Stock Dividends And Other Adjustments | $4.73 Million |
Gross Profit | $947.39 Million |
Selling, General, and Administrative Expenses | $456.75 Million |
Nonoperating Income/Loss | $-310.88 Million |
Income Tax Expense/Benefit | $23.32 Million |
Benefits Costs and Expenses | $2.80 Billion |
Basic Average Shares | $331.46 Million |
Diluted Earnings Per Share | $-0.85 |
Net Income/Loss Available To Common Stockholders, Basic | $-184.45 Million |
Income/Loss From Continuing Operations After Tax | $-146.48 Million |
Diluted Average Shares | $328.54 Million |
Operating Income/Loss | $187.73 Million |
Participating Securities, Distributed And Undistributed Earnings/Loss, Basic | $4.73 Million |
Net Income/Loss Attributable To Parent | $-179.73 Million |
Other Operating Expenses | $120.38 Million |
Cost Of Revenue | $1.73 Billion |
Balance Sheet
October 1, 2023 to September 30, 2024
Metric | Value |
---|---|
Wages | $64.90 Million |
Equity Attributable To Parent | $-93.43 Million |
Assets | $3.46 Billion |
Other Current Liabilities | $795.31 Million |
Other Non-current Liabilities | $5.15 Million |
Liabilities | $3.49 Billion |
Inventory | $596.36 Million |
Long-term Debt | $2.39 Billion |
Intangible Assets | $780.19 Million |
Equity | $-93.57 Million |
Liabilities And Equity | $3.46 Billion |
Temporary Equity | $59.89 Million |
Current Liabilities | $1.10 Billion |
Current Assets | $1.51 Billion |
Other Current Assets | $916.93 Million |
Other Non-current Assets | $736.48 Million |
Accounts Payable | $235.00 Million |
Fixed Assets | $431.02 Million |
Noncurrent Assets | $1.95 Billion |
Equity Attributable To Noncontrolling Interest | $-135,000.00 |
Noncurrent Liabilities | $2.40 Billion |
Historical Dividends
Announcement Date | Payment Date | Record Date | Amount | Frequency |
---|---|---|---|---|
No historical dividends |
Boost your savings and earn 4.35% APY with a Marcus by Goldman Sachs savings account, a rate that's 8x the national averagewhen signing up with Financhle. No fees, no minimum deposits, backed by the financial expertise of Goldman Sachs. Terms apply.
ⓒ 2024 Financhle. All Rights Reserved.